Sheila M Hegde1, Brian Claggett1, Amil M Shah1, Eldrin F Lewis1, Inder Anand1, Sanjiv J Shah1, Nancy K Sweitzer1, James C Fang1, Bertram Pitt1, Marc A Pfeffer1, Scott D Solomon2. 1. From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.M.H., B.C., A.M.S., E.F.L., M.A.P., S.D.S.); Department of Cardiology, VA Medical Center and Division of Cardiovascular Medicine, University of Minnesota, Minneapolis (I.A.); Cardiology Division, Northwestern University, Chicago, IL (S.J.S.); Division of Cardiology, University of Arizona, Tucson (N.K.S.); Division of Cardiovascular Medicine, University of Utah, Salt Lake City (J.D.F.); and Cardiovascular Medicine Division, University of Michigan School of Medicine, Ann Arbor (B.P.). 2. From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.M.H., B.C., A.M.S., E.F.L., M.A.P., S.D.S.); Department of Cardiology, VA Medical Center and Division of Cardiovascular Medicine, University of Minnesota, Minneapolis (I.A.); Cardiology Division, Northwestern University, Chicago, IL (S.J.S.); Division of Cardiology, University of Arizona, Tucson (N.K.S.); Division of Cardiovascular Medicine, University of Utah, Salt Lake City (J.D.F.); and Cardiovascular Medicine Division, University of Michigan School of Medicine, Ann Arbor (B.P.). ssolomon@rics.bwh.harvard.edu.
Abstract
BACKGROUND:Physical activity (PA) is inversely associated with adverse cardiovascular outcomes in healthy populations, but the impact of physical activity in patients with heart failure (HF) with preserved ejection fraction is less well characterized. METHODS: The baseline self-reported PA of 1751 subjects enrolled in the Americas region of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With anAldosterone Antagonist) was categorized as poor, intermediate, or ideal PA with American Heart Association criteria. PA was related to the primary composite outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest), its components, and all-cause mortality with the use of multivariable Cox models. RESULTS: The mean age at enrollment was 68.6±9.6 years. Few patients met American Heart Association criteria for ideal activity (11% ideal, 14% intermediate, 75% poor). Over a median follow-up of 2.4 years, the primary composite outcome occurred in 519 patients (397 HF hospitalizations, 222 cardiovascular deaths, and 6 aborted cardiac arrests). Compared with those with ideal baseline PA, poor and intermediate baseline PA was associated with a greater risk of the primary outcome (hazard ratio [HR], 2.05; 95% confidence interval [CI], 1.28-3.28; HR, 1.95; 95% CI, 1.15-3.33, respectively), HF hospitalization (HR, 1.93; 95% CI, 1.16-3.22; HR, 1.84; 95% CI, 1.02-3.31), cardiovascular mortality (HR, 4.36; 95% CI, 1.37-13.83; HR, 4.05; 95% CI, 1.17-14.04), and all-cause mortality (HR, 2.95; 95% CI, 1.44-6.02; HR, 2.05; 95% CI, 0.90-4.67) after multivariable adjustment for potential confounders. CONCLUSIONS: In patients with HF with preserved ejection fraction, both poor and intermediate self-reported PA were associated with higher risk of HF hospitalization and mortality. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT00094302.
RCT Entities:
BACKGROUND: Physical activity (PA) is inversely associated with adverse cardiovascular outcomes in healthy populations, but the impact of physical activity in patients with heart failure (HF) with preserved ejection fraction is less well characterized. METHODS: The baseline self-reported PA of 1751 subjects enrolled in the Americas region of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) was categorized as poor, intermediate, or ideal PA with American Heart Association criteria. PA was related to the primary composite outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest), its components, and all-cause mortality with the use of multivariable Cox models. RESULTS: The mean age at enrollment was 68.6±9.6 years. Few patients met American Heart Association criteria for ideal activity (11% ideal, 14% intermediate, 75% poor). Over a median follow-up of 2.4 years, the primary composite outcome occurred in 519 patients (397 HF hospitalizations, 222 cardiovascular deaths, and 6 aborted cardiac arrests). Compared with those with ideal baseline PA, poor and intermediate baseline PA was associated with a greater risk of the primary outcome (hazard ratio [HR], 2.05; 95% confidence interval [CI], 1.28-3.28; HR, 1.95; 95% CI, 1.15-3.33, respectively), HF hospitalization (HR, 1.93; 95% CI, 1.16-3.22; HR, 1.84; 95% CI, 1.02-3.31), cardiovascular mortality (HR, 4.36; 95% CI, 1.37-13.83; HR, 4.05; 95% CI, 1.17-14.04), and all-cause mortality (HR, 2.95; 95% CI, 1.44-6.02; HR, 2.05; 95% CI, 0.90-4.67) after multivariable adjustment for potential confounders. CONCLUSIONS: In patients with HF with preserved ejection fraction, both poor and intermediate self-reported PA were associated with higher risk of HF hospitalization and mortality. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT00094302.
Authors: Yogesh N V Reddy; Masaru Obokata; Aaron D Jones; Gregory D Lewis; Sanjiv J Shah; Omar F Abouezzedine; Marat Fudim; Brooke Alhanti; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug Journal: J Card Fail Date: 2020-08-19 Impact factor: 5.712
Authors: Mauro F F Mediano; Eric S Leifer; Lawton S Cooper; Steven J Keteyian; William E Kraus; Robert J Mentz; Jerome L Fleg Journal: JACC Heart Fail Date: 2018-12 Impact factor: 12.035
Authors: Rachel C Kelley; Lauren Betancourt; Andrea M Noriega; Suzanne C Brinson; Nuria Curbelo-Bermudez; Dongwoo Hahn; Ravi A Kumar; Eliza Balazic; Derek R Muscato; Terence E Ryan; Robbert J van der Pijl; Shengyi Shen; Coen A C Ottenheijm; Leonardo F Ferreira Journal: J Appl Physiol (1985) Date: 2021-11-18
Authors: Eiran Z Gorodeski; Parag Goyal; Scott L Hummel; Ashok Krishnaswami; Sarah J Goodlin; Linda L Hart; Daniel E Forman; Nanette K Wenger; James N Kirkpatrick; Karen P Alexander Journal: J Am Coll Cardiol Date: 2018-05-01 Impact factor: 24.094
Authors: Carsten Tschöpe; Christoph Birner; Michael Böhm; Oliver Bruder; Stefan Frantz; Andreas Luchner; Lars Maier; Stefan Störk; Behrouz Kherad; Ulrich Laufs Journal: Clin Res Cardiol Date: 2017-10-10 Impact factor: 5.460